Jeisys Medical Inc
KOSDAQ:287410
Jeisys Medical Inc
Depreciation & Amortization
Jeisys Medical Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jeisys Medical Inc
KOSDAQ:287410
|
Depreciation & Amortization
₩4.5B
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Classys Inc
KOSDAQ:214150
|
Depreciation & Amortization
₩14.4B
|
CAGR 3-Years
65%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
W
|
Won Tech Co Ltd
KOSDAQ:336570
|
Depreciation & Amortization
₩2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Viol Co Ltd
KOSDAQ:335890
|
Depreciation & Amortization
₩1.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Seers Technology Co Ltd
KOSDAQ:458870
|
Depreciation & Amortization
₩1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
NextBioMedical Co Ltd
KOSDAQ:389650
|
Depreciation & Amortization
₩492.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jeisys Medical Inc
Glance View
Jeisys Medical, Inc. manufactures and develops products used by plastic surgeons, dermatologist, physicians and health professionals. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-05-08. The firm manufactures and sells skin care medical devices such as ULTRAcel Q+, POTENZA, and other products. In addition, the Company also provides consumables such as cartridges and tips.
See Also
What is Jeisys Medical Inc's Depreciation & Amortization?
Depreciation & Amortization
4.5B
KRW
Based on the financial report for Jun 30, 2024, Jeisys Medical Inc's Depreciation & Amortization amounts to 4.5B KRW.
What is Jeisys Medical Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
63%
Over the last year, the Depreciation & Amortization growth was 23%. The average annual Depreciation & Amortization growth rates for Jeisys Medical Inc have been 63% over the past three years .
